Trials / Unknown
UnknownNCT00733174
Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Denver Research Institute · Academic / Other
- Sex
- All
- Age
- 25 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Subjects with impaired glucose tolerance will be randomized to either rosiglitazone or placebo for a 18 month period. The study will look at baseline, 12 month and 18 month data for exercise tolerance, coronary artery calcification and diabetes indicators.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rosiglitazone | tablet |
| DRUG | Placebo |
Timeline
- Start date
- 2004-03-01
- Primary completion
- 2009-01-01
- First posted
- 2008-08-12
- Last updated
- 2008-08-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00733174. Inclusion in this directory is not an endorsement.